Key Insights from the HER2CLIMB Trial
Panelists discuss key data from the HER2CLIMB study, which evaluates the efficacy of tucatinib (Tukysa) in combination with trastuzumab (Herceptin) and capecitabine (Xeloda) for patients with advanced HER2+ breast cancer, highlighting outcomes across patient subgroups and the clinical significance of findings related to patients with measurable baseline intracranial disease.
EP: 1.Overview of HER2 Breast Cancer
EP: 2.HER2+ Breast Cancer Diagnosis: Insights From Patients and Clinicians
EP: 3.Coordinating Care for HER+ Breast Cancer Patients: A Multidisciplinary Approach
EP: 4.Multidisciplinary Care of HER2+ Breast Cancer: A Patient Perspective
EP: 5.Tailoring Patient Education and Resources in HER2+ Breast Cancer
EP: 6.Navigating HER2+ Breast Cancer Treatment: A Patient's Journey
EP: 7.Navigating Systemic Therapy Options in HER2+ Breast Cancer
Now Viewing
EP: 8.Key Insights from the HER2CLIMB Trial
EP: 9.Key Insights From the DEBBRAH and HER2CLIMB-02 Studies
EP: 10.BRIDGET Trial: Strategies in Maintenance Therapy for HER2+ Breast Cancer with Brain Metastases
EP: 11.Preparing Patients for Treatment: Education, Administration and Adverse Effect Management in HER2+ Breast Cancer
EP: 12.Patient Perspectives on Managing Adverse Effects from Capecitabine, Trastuzumab, and Tucatinib
EP: 13.Comprehensive Supportive Care for Metastatic HER2+ Breast Cancer
EP: 14.Patient Perspective: Key Aspects of Supportive Care in the HER2+ Breast Cancer Journey
EP: 15.Future Perspectives in HER2+ Breast Cancer
EP: 16.Closing Thoughts: Key Messages for Clinicians and Patients in the Treatment of HER2+ Breast Cancer
EP: 17.Discussing, Managing, and Treating HER2+ Breast Cancer From the Patient’s Perspective
- Dr Iyengar: Briefly discuss key data from the HER2CLIMB study, evaluating tucatinib in combination with trastuzumab and capcitabine capecitabine for patients with advanced HER2+ breast cancer.
- Please comment on the efficacy outcomes across patient subgroups.
- What is the clinical significance for findings in patients with advanced HER2+ breast cancer and measurable baseline intracranial disease?
Recent Videos
Related Content
